Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from a randomized vehicle-controlled phase III study in Europe

British Journal of Dermatology

Volumn 152, Issue 5, 2005, Pages 939-947

  Schulze, Haas Joachim ^a   Cribier, B ^b   Requena, L ^c   Reifenberger, J ^d   Ferrandiz C ^e   Garcia Diez, A ^f   Tebbs, V ^g   McRae, S ^h  

^a Fachklinik Hornheide   (Germany)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g 3M Drug Delivery Systems   (United Kingdom)

^h 3M COMPANY   (United States)

Author keywords

Imiquimod; Immune response modifier; Randomized controlled trial; Superficial basal cell carcinoma

Indexed keywords

CYTOKINE; IMIQUIMOD; TOLL LIKE RECEPTOR 7;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BLEEDING; CANCER REGRESSION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EROSION; ERYTHEMA; EVALUATION; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN CRUSTING; SKIN MANIFESTATION; SKIN SCABBING; SUPERFICIAL CANCER;

ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 18944395052     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06486.x     Document Type: Article

References (15)

1. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003; 327:794-8.
2. MacKie RM. Epidermal skin tumours. In: Textbook of Dermatology (Champion RH, Burton JL, Burns DA, Breathnach SM, eds), 6th edn, Vol. 2. Oxford: Blackwell Science, 1998; 1679-85.
3. Morales-Ducret CRJ, van de Rijn M, LeBrun DP, Smoller BR. Bcl-2 expression in primary malignancies of the skin. Arch Dermatol 1995; 131:909-12.
4. Norris DA. Differential control of cell death in the skin. Arch Dermatol 1995; 131:945-8.
5. Hill LL, Ouhtit A, Loughlin SM et al. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 1999; 285:898-900.
6. Muller M, Wilder S, Bannasch D et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188:2033-45.
7. Miller RL, Gerster JF, Owens ML et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21:1-14.
8. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200.
9. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44:807-13.
10. Geisse J, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47:390-8.
11. Beutner KR, Geisse JK, Helman D et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41:1002-7.
12. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124:869-71.
13. Geisse J, Caro I, Lindholm J et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50:722-33.
14. Schön M, Bong AB, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95:1139-49.
15. Schön M, Gregor Wienrich B, Drewniok C et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004; 122:1266-76.